Vaxxas Awarded US$5 million Grant for Clinical Study of Measles and Rubella Vaccination
Vaxxas received a Gates Foundation grant to run first-in-human trials of its microneedle patch vaccine for measles and rubella, building on an earlier preclinical grant from the same funder.